WilmerHale Advises Underwriters in Disc Medicine’s Upsized $450 Million Public Offering 

WilmerHale Advises Underwriters in Disc Medicine’s Upsized $450 Million Public Offering 

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale advised the underwriters in the public offering of 6,000,000 shares of common stock of Disc Medicine, Inc. (Disc) (Nasdaq: IRON). Disc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. Disc received approximately $450 million in gross proceeds, excluding underwriting discounts and commissions and other offering-related expenses. In addition, Disc granted the underwriters a 30-day option to purchase up to 900,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.

The WilmerHale team was led by Lisa Firenze and Andrea Sorrentino and included Whitley Horning and Isaiah Chatman, with assistance from Barish Ozdamar on intellectual property matters, Bruce Manheim on regulatory matters and Meghan Walsh and Ben Kelsey on tax matters.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel